Therapeutic phosphodiesterase inhibitors
CA 2357950 C · Owner: Lakewood-Amedex, Inc. · Inventors: Thompson, Terry; Arrow, Amy; Dale, Roderic M. K.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This patent describes the invention of a series of novel therapeutic oligonucleotide polymers targeted at inhibiting expression of genes coding for Phosphodiesterase 4. They are useful as analytical tools in the study of individual PDE isoforms and in the therapeutic treatment of depression thrombosis, cystic fibrosis, gastric lesions pulmonary hypertension, glaucoma, multiple sclerosis atopic dermatitis, asthma and other allergic disorders as well as other illnesses in which an increase of cyclic AMP or a decrease in phosphodiesterase levels is useful.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 15, 1999 and granted July 23, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 15, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 15, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.